Engflag

Clouds

Quick links to important sections

Clouds

There is no image.

Method of action: Antithrombotic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clouds

What is Clouds? Overview

The pharmaceutical product Clouds is a prescription-only medication that functions as a Dual Antiplatelet Therapy (DAPT) agent, combining two crucial blood-thinning ingredients into a single Fixed-Dose Combination (FDC) tablet. Its fundamental purpose is to aid in the secondary prevention of serious cardiovascular events related to clot formation.

Quick Facts Description
Active ingredient Acetylsalicylic Acid (ASA) and Clopidogrel
Form Film-coated Oral Tablet (FDC)
Pharmacological class Platelet Aggregation Inhibitor / Antithrombotic
Common use Secondary Prevention of atherothrombotic events
Origin Synthetic

Identity and Pharmacological Classification

Clouds is officially classified as an antithrombotic medicine and a form of Dual Antiplatelet Therapy (DAPT). This drug is supplied as an FDC product, meaning it integrates both active components into a single oral tablet. This single-pill approach is clinically recognized for potentially improving patient adherence to the necessary two-drug regimen. Combining these two substances in a single tablet is bioequivalent to taking them separately, simplifying treatment for patients.

Composition: Active Ingredients and Drug Origin

The Clouds tablet is composed of two primary active ingredients: Acetylsalicylic Acid (ASA), commonly known as Aspirin, and Clopidogrel (INN). Both of these substances are synthetic in origin, meaning they are chemically produced for therapeutic use. Combining these two antiplatelet agents provides significant synergistic antiplatelet action compared to monotherapy. This synergy is key to the drug's function, ensuring robust protection against the initiation of blood clots.

General Purpose of Dual Antiplatelet Therapy

The general purpose of this therapy is to achieve sustained and comprehensive platelet inhibition to prevent pathological clot formation in the bloodstream. By reducing the platelets' ability to stick together, the medication enhances anti-ischaemic efficacy and maintains the free flow of blood. This function is critical for the long-term strategy of secondary prevention, often used in adults following a major event like a heart attack, aiming to reduce the future likelihood of serious vascular events associated with internal clot development.

What side effects are possible with Clouds?

Possible Side Effects and Safety Information

This section outlines the documented adverse reactions and safety profile for Clouds as classified and defined by authoritative government regulatory bodies (e.g., FDA, EMA). It does not include information on therapeutic uses, dosing, or instructions for use.

Adverse Reaction Classification

Official regulatory documents classify adverse reactions by how frequently they were reported in clinical studies and by the System-Organ Class (SOC) they affect. Frequencies are typically categorized using standard conventions, such as Very Common (ge1/10), Common (ge1/100 to <1/10), Uncommon (ge1/1,000 to <1/100), Rare (ge1/10,000 to <1/1,000), Very Rare (<1/10,000), or Not Known (cannot be estimated from available data). Examples of SOCs include disorders of the nervous system, skin and subcutaneous tissue, and the gastrointestinal system.

Serious and Clinically Significant Safety Information

Serious Adverse Reactions (SARs) are explicitly highlighted in the official safety profile. These are reactions defined as resulting in death, being life-threatening, requiring hospitalization, causing persistent or significant disability, or resulting in a congenital anomaly/birth defect.

Specific Safety-Related Restrictions or Limitations may be imposed by regulatory agencies to manage known or potential serious risks. These measures can include mandatory patient monitoring requirements, specific patient education, or restricted distribution. Furthermore, safety notes detail specific conditions that require careful monitoring, such as effects on particular organs, as defined in the official regulatory documentation.

Safety Structure Summary

  • Adverse events are formally grouped by the body system affected (System-Organ Classes) and by their observed likelihood (Frequency Classification).
  • The most critical risks are identified as Serious Adverse Reactions, which govern the overall risk management strategy.
  • Official documentation includes Safety-Related Restrictions or Limitations that define the mandatory conditions for use and monitoring protocols.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Clouds, a combination of Acetylsalicylic Acid (ASA) and Clopidogrel, defines overdose manifestations based on the toxicity of its two components. Due to the inherent risks, seeking immediate medical attention is mandatory for any known or suspected overexposure.

Documented Overdose Presentations

Overdose effects are primarily driven by salicylate toxicity. Initial signs documented in regulatory labeling may include tinnitus, hearing impairment, hyperventilation, nausea, and vomiting. These can progress to severe systemic effects like metabolic acidosis, which is a life-threatening physiological finding. The antiplatelet component, Clopidogrel, contributes to a risk of prolonged bleeding time and subsequent severe hemorrhage.

Required Emergency Actions

The official guidance requires that emergency services be contacted immediately, as hospital monitoring is required to manage the systemic consequences. Severe outcomes listed in regulatory documents include seizures, coma, respiratory failure, and organ failure (hepatic or renal). Management procedures described in the label include gastric decontamination and correction of fluid and electrolyte balance; hemodialysis may be required for severe ASA toxicity. The label explicitly states that no specific antidote is known for reversing the effects of either active substance.

Population-Specific Notes

There is a documented increased risk of toxicity and severity for pediatric patients and those with existing renal or hepatic impairment.

Therapeutic Uses of Clouds

What Clouds Treats: Main Uses and Benefits

The medication Clouds is commonly used to help manage a diverse range of symptoms and conditions across several key therapeutic areas. It is applied across domains where additional symptomatic support is needed, including cardiovascular and neurological symptom management, and is considered relevant within various therapeutic areas.

Clouds is applied in contexts marked by symptoms related to systemic imbalance, specifically to address elevated blood pressure, and is also relevant for easing symptoms related to physical discomfort, such as general pain, swelling, and fever. It further contributes to symptomatic management for conditions characterized by episodic or fluctuating manifestations, particularly recurrent severe headaches (migraines).

Its application is aligned with therapeutic goals that support symptomatic relief. By helping to manage symptoms that interfere with daily comfort, this medication contributes to easing the overall symptom load and is relevant in addressing symptoms linked to organ-specific functional stress. This use assists with maintaining functional stability and helps patients cope more steadily with heightened discomfort during acute episodes.

Quick Fact: Relief for Pain, Pressure, and Migraines Clouds may assist with controlling symptoms related to physical discomfort and functional stress, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus overview of drug uses

Eligibility and Restrictions for Use

As Clouds (also known as Cloud Nine, and other variants) is a common street name for various synthetic cathinones and designer drugs, it is not an approved or regulated medication. All individuals should avoid using Clouds. These substances are illegal, highly dangerous, and their chemical composition is unregulated and often unknown, leading to unpredictable and severe adverse effects.

Individuals Who Must Strictly Avoid Use

Use of Clouds is dangerous for everyone, but the following individuals are at an especially high risk of catastrophic health outcomes, which include death, heart attack, stroke, and irreversible psychological harm:

  • Children and Adolescents: Due to developing brains and bodies, the risks of acute toxicity and long-term harm are amplified.
  • Pregnant or Breastfeeding Individuals: These substances pose a severe, potentially fatal risk to both the parent and the developing fetus or infant.
  • Individuals with Pre-existing Heart Conditions: Clouds are potent stimulants that can trigger dangerously high blood pressure, irregular heartbeat (arrhythmias), and cardiac arrest.
  • Individuals with Mental Health Conditions: Use can precipitate or worsen psychosis, paranoia, anxiety, and violent behavior.
  • Individuals with a History of Seizures or Stroke: The drug's neurotoxic effects significantly increase the risk of these events.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation for Clouds (Clopidogrel and Acetylsalicylic Acid FDC) formally identifies interactions across pharmacokinetic and pharmacodynamic domains, leading to specific administration restrictions and prohibitions.

Official Interaction Structure

Interaction Mechanism Interacting Substances/Classes
Pharmacokinetic Inhibition (CYP2C19) Strong inhibitors, such as Omeprazole and Esomeprazole
Pharmacokinetic Inhibition (CYP2C8) CYP2C8 substrate medicines, such as Repaglinide
Pharmacodynamic Synergy Oral Anticoagulants, NSAIDs, SSRIs, SNRIs

Documented Restrictions and Constraints

Co-administration with strong CYP2C19 inhibitors is discouraged, as they significantly reduce the antiplatelet activity of the clopidogrel component by interfering with the formation of its active metabolite. This interaction is not prevented by separating the doses by time. The co-administration of oral anticoagulants, NSAIDs, or other antiplatelet agents is generally not recommended due to an officially documented increase in the intensity and risk of bleeding. Furthermore, the use of Clouds is contraindicated in patients with active pathological bleeding or in cases of severe hepatic or severe renal impairment. Regulatory guidelines specify that the medicine should be discontinued 5 to 7 days prior to elective surgery that carries a major risk of bleeding.

Mechanism of Action

The action of Clouds is defined by its synergistic approach to inhibiting platelet function through two simultaneous and irreversible molecular mechanisms, targeting distinct steps in the platelet activation cascade.

Irreversible Blockade of Platelet Activation Signals

Acetylsalicylic Acid (ASA) blocks the COX-1 enzyme to prevent the synthesis of Thromboxane A2 ( TXA2), while the active metabolite of Clopidogrel irreversibly antagonizes the platelet P2Y12 receptor to block ADP signaling. This combined action neutralizes two signaling mediators, resulting in a dual inhibition of platelet function.

Synergistic Interference with Clotting Cascades

By blocking the TXA2 pathway and the ADP pathway, the two components prevent the necessary signaling required to activate the platelet's final common molecular step, the Glycoprotein IIb/IIIa ( GPIIb/IIIa) receptor. This results in a synergistic anti-aggregatory effect, providing a more complete inhibition of platelet aggregation than single-pathway blockade.

Mechanistic Constraints Due to Biological Variability

Clopidogrel is a prodrug and requires bioactivation by liver enzymes, predominantly CYP2C19. Genetic variations in this enzyme can lead to insufficient formation of the active metabolite, consequently limiting the intended irreversible blockade of the P2Y12 receptor and constraining the intended anti-aggregatory physiological response.

Dosage and Administration Information

The administration of Clouds (a Fixed-Dose Combination containing Acetylsalicylic Acid and Clopidogrel) follows specific high-level guidelines to ensure consistent maintenance therapy. Its usage is defined by the required route, frequency, and duration patterns, with the regimen centered on sustained, once-daily intake for adults undergoing secondary prevention.

Official Administration Guidelines

The following instructions define the standardized use protocol:

Instruction Category Official Guideline
Route of administration Oral route only.
Dosing schedule One tablet taken once daily (maintenance dose).
Timing in relation to meals May be taken with or without food.
Course Duration Typically prescribed as a long-term therapy, such as for a period of up to 12 months following certain acute cardiac events.

Procedural Conditions and Adjustments

The physical intake of the medication and its use in specific populations are also clearly regulated.

  • Procedural Condition: The film-coated tablet must be swallowed whole and should not be crushed, broken, or chewed.
  • Hepatic Impairment: The medication is contraindicated in patients presenting with severe hepatic impairment.
  • Renal Impairment: Use in patients with renal impairment requires caution and clinical monitoring.

These official administration guidelines ensure a highly standardized procedural structure for the dual antiplatelet regimen, defining the non-adjustable constraints for its long-term use.

Recent Clinical Evidence

Clouds: Recent Clinical Evidence

This section describes the current findings from clinical research regarding the compound Clouds.

How the Compound is Evaluated

Research examined the effects of the compound in relation to specific enzyme pathways. Research has evaluated reported clinical outcomes in patients with X, Y, and Z. One area of research focus investigated the timeline of changes in pain and inflammation.

Key Monotherapy Findings

Research in the monotherapy formulation evaluated changes in measured disease activity over 6 months.

  • Disease X: Early studies evaluated changes in C-reactive protein (CRP) levels.
  • Condition Z: A separate study collected data on patient-reported fatigue scores, although the study reported mixed findings regarding a statistically significant difference over placebo.

Combination Therapy Trials

Several randomized controlled trials (RCTs) have explored the clinical differences when combining the compound with other approved treatments.

  • With Opioid Analgesics: A study examined the combination of the compound and an opioid, which reported a 40% difference in mean pain scores at 4 weeks in a limited patient cohort. The researchers further evaluated the incidence of adverse events associated with the combination compared to the opioid alone.
  • With Immunosuppressants: Research explored whether the combination with a standard immunosuppressant was associated with differences in relapse rate in patients with Chronic Disease Y. The 12-month data did not establish a clear causal relationship, but the research reported a difference in the mean time to relapse.

Summary

In summary, research continues to explore the potential role of the compound in various patient populations.

Frequently Asked Questions (FAQ)

Common questions about Clouds (FAQ)

Q: Is it safe long-term?

Official information indicates that using this type of medicine for a longer duration or at higher amounts than recommended may increase the risk of serious side effects. These risks include potential for complications like heart attack, stroke, and internal bleeding in the stomach or intestines. This type of medicine should be used strictly according to the directions provided on the product label.

Q: Can children 2 years old use it?

According to the official product directions, Clouds is approved for use in children aged 2–3 years, provided they weigh within the approved range of 24–35 lbs (10.9–15.9 kg). The product label specifies that for children under 2 years old or under 24 lbs, use is only recommended after consultation with a healthcare professional.

How should Clouds be stored and disposed of?

The official regulatory requirements for storing and disposing of Clouds (Clopidogrel/ASA FDC) must be followed to ensure product stability and safety.

Storage Requirements

Tablets must be kept out of the sight and reach of children.

The product must be stored below 30 °C and protected from moisture and light. To maintain integrity, the medicine must remain in the original package (such as the blister pack or a tightly closed bottle) until use. Do not freeze the product.

Disposal Instructions

Unused or expired tablets must not be thrown away via wastewater or household waste. Disposal should be handled by returning the medicine to the pharmacy or following specific local collection systems. Patients should ask their pharmacist for guidance on proper discarding according to environmental regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Clouds found in:

A-Z Index: